Press release
Respiratory Syncytial Virus Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Dive into DelveInsight's comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from Respiratory Syncytial Virus Pipeline Report
* On March 20, 2026- GlaxoSmithKline conducted a phase 3 study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.
* On March 17, 2026- Shionogi initiated a phase 2b study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
* On March 05, 2026- Zhuhai Trinomab Pharmaceutical Co., Ltd . conducted a study adopts an adaptive seamless dose selection design and consists of two parts: Part 1 is a phase 2b dose ranging trial which will support to determine the dose for Part 2, the phase 3 trial. The study population includes early and mid-term preterm infants [gestational age (GA)35 weeks 0 day] and late preterm infants or full-term infants ( greater than or equal to 35 weeks 0 day GA), with or without Congenital Heart Disease (CHD) or premature infants Chronic Lung Disease (CLD). A total of approximately 2250 infants will be randomized 2:1 to receive either TNM001 or placebo. All subjects will be followed for 240 days after dosing. This study will be conducted in appropriately 50 sites in China.
* DelveInsight's Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
* The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
* Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Respiratory Syncytial Virus Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Respiratory Syncytial Virus Pipeline Report also highlights the unmet needs with respect to the Respiratory Syncytial Virus.
Respiratory Syncytial Virus Overview
RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults. RSV spreads through respiratory droplets and can survive on surfaces for several hours. While most infections are self-limiting, severe cases may require hospitalization, and preventive measures such as good hygiene and vaccination are essential in managing its spread.
Respiratory Syncytial Virus Emerging Drugs Profile
* Clesrovimab: Merck Sharp & Dohme
Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
* IVX A12: AstraZeneca
IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults greater than or equal to 60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax's RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
* MV-012-968: Meissa Vaccines, Inc
MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naive children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company's proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline @ New Respiratory Syncytial Virus Drugs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Respiratory Syncytial Virus Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
* Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market
Respiratory Syncytial Virus Companies
AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Respiratory Syncytial Virus Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Respiratory Syncytial Virus Pipeline Report
* Coverage- Global
* Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
* Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
* Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Respiratory Syncytial Virus Therapies and clinical trials @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Respiratory Syncytial Virus (RSV): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Respiratory Syncytial Virus (RSV) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Respiratory Syncytial Virus (RSV) Collaboration Deals
* Late Stage Products (Phase III)
* Clesrovimab: Merck Sharp & Dohme
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IVX A12: AstraZeneca
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MV-012-968: Meissa Vaccines, Inc
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Respiratory Syncytial Virus (RSV) Key Companies
* Respiratory Syncytial Virus (RSV) Key Products
* Respiratory Syncytial Virus (RSV)- Unmet Needs
* Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
* Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
* Respiratory Syncytial Virus (RSV) Analyst Views
* Respiratory Syncytial Virus (RSV) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=respiratory-syncytial-virus-clinical-trial-pipeline-appears-robust-with-50-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight here
News-ID: 4440576 • Views: …
More Releases from ABNewswire
A Story of Survival, Sibling Love, and Unbreakable Spirit Rises from the Depths …
Under Cajun Wings by Richard E. Nicholson Jr. is a heartfelt novel set in the Atchafalaya Swamp of Southern Louisiana, following young siblings Daniel and Josee as they endure hardship, isolation, and fear while relying on each other to survive. Rich in emotional depth and Cajun atmosphere, the story explores sibling love, resilience, hope, and the unbreakable human spirit in the face of adversity.
Under Cajun Wings is a heartfelt and…
Richard Nicholson's The Betrayal - A Wartime and Peacetime Novel with Multidimen …
Richard Nicholson's The Betrayal is a historical fiction novel set in the Vietnam and post-war eras, following Captain Bryce Tucker and Nuna Polinski through love, loss, betrayal, and survival. Drawing on Nicholson's experience as a Vietnam veteran, the novel blends wartime realism, emotional conflict, espionage, and suspense in a gripping story of loyalty, justice, and the lasting consequences of war.
While many romance novels unfold in peaceful modern settings, some find…
How EmpoweredPagesCo Is Leading a Quiet Revolution in Confidence-Building Throug …
As conversations around self-worth and mental wellness continue to grow, EmpoweredPagesCo is meeting the moment with apparel that does more than cover the body. The brand's collection of empowering t-shirts and hoodies is helping people across all walks of life turn getting dressed into an act of personal affirmation.
The connection between clothing and confidence is well documented. Studies in psychology have explored the concept of enclothed cognition, the idea that…
Sunswell Strengthens Global Leadership in Beverage Packaging Solutions with Adva …
Sunswell delivers liquid packaging solutions across 80+ countries with high-efficiency systems supporting global beverage production.
Image: https://www.abnewswire.com/upload/2026/04/3ad45e5cd7a841d4fb77cd049bf0b8b3.jpg
Sunswell [https://www.sunswell.com/], a leading equipment supplier in the liquid packaging industry, continues to expand its global footprint by delivering advanced turnkey solutions for beverage and liquid production. With a strong foundation in engineering excellence and a growing portfolio of international projects, the company is reinforcing its position as a trusted partner for manufacturers seeking efficient,…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
